Led · Series A · May 2026

Aerska is developing delivery technologies intended to enable systemic delivery of RNA medicines to the brain to treat serious neurological diseases. The company is focused on improving selectivity of RNAi payload delivery and on approaches that could target multiple disease pathways simultaneously. Aerska announced an additional $10M investment from GHIC as part of its Series A, indicating ongoing Series A financing activity. The company positions the GHIC investment as a partnership to advance its platform toward clinical or translational goals. No public operating metrics or founding date were disclosed in the announcement.

Participated · Series C · Mar 2026

Terrestrial Bio (formerly Vaxess Technologies) is advancing a proprietary microarray patch (MAP) and preloaded applicator platform that applies a patch resembling an adhesive bandage and releases bioactive tips into the skin which dissolve and rapidly deliver their payload. The MAP platform is designed for self-administration, is temperature-stable, and eliminates the need for medical sharps or refrigeration. The company positions the technology for precise, controlled delivery of a wide range of therapeutics. Terrestrial is led by CEO Rachel Sha and is based in Woburn, MA. To support late-stage clinical development and early commercial entry, the company signed a lease for a more than 40,000-square-foot manufacturing facility at Allston Labworks and plans to incorporate automation, robotics, computer vision, and quality-control processes during buildout beginning in 2026.

Participated · Series A · Feb 2026

Prenosis develops AI-powered diagnostic and therapeutic tools that tailor care to each patient’s unique biological profile. Its core Immunix platform aggregates deep biological data to create diagnostics such as the Sepsis ImmunoScore, the first FDA-authorized AI test for sepsis. The company aims to commercialize ImmunoScore while continuing to expand its portfolio of biology-based diagnostics. Plans include deploying the platform in up to 40 academic medical centers to establish a precision-medicine clinical-trial network, enabling rapid recruitment of patients with specific biological signatures. Led by CEO Bobby Reddy, Jr., PhD, Prenosis positions itself at the intersection of data science, biology, and clinical practice to improve outcomes in critical conditions. The new capital will accelerate product rollout and broaden clinical integration efforts, supporting the company’s mission to personalize critical-care medicine.

Participated · Series C · Jan 2026

Antheia is a biosynthesis company focused on transforming pharmaceutical manufacturing through engineered microorganisms that produce complex active pharmaceutical ingredients (APIs). The firm employs its advanced biosynthesis platform to generate critical drug ingredients domestically, reducing reliance on fragile global supply chains. Under an ongoing collaboration with the U.S. government’s BioMaP-Consortium, Antheia will scale commercial production of two essential pharmaceutical compounds in the United States. The company positions its technology as a solution to longstanding vulnerabilities in healthcare supply chains and aims to build a more resilient, on-shore source of medicines for the American market. To date, Antheia has secured $21 million in federal project investment dedicated to this initiative, including a recent $9 million expansion award. These funds will be deployed to increase manufacturing capacity and accelerate the company’s path to large-scale commercialization. No additional operating metrics or revenue figures were disclosed in the article.

Led · Series A · Jan 2025

Micron Biomedical develops a dissolvable microarray-based, needle-free platform for administration of drugs and vaccines. Its proprietary technology is designed to enable injection-free, painless and simple or self-administration, and to reduce or eliminate cold-chain requirements. The platform aims to enhance safety and efficacy while improving patient compliance. The company is led by CEO Steve Damon and is based in Atlanta, GA. Micron intends to use newly raised funds to expand operations and its R&D sector. Financially, the company extended its Series A to over $33M following the latest financing. Micron Biomedical is a clinical-stage life science company developing dissolvable microarray-based products for injection-free, painless administration of drugs and vaccines. Its core product is a microarray technology that reduces or eliminates cold chain requirements and enables community health workers to vaccinate quickly by applying a patch and pressing a button to confirm administration. Micron reported successful phase I/II clinical data in the Gambia across adults, toddlers, and infants as young as nine months using a leading commercial measles-rubella vaccine delivered via its microarray. The company plans to build a commercial-scale manufacturing facility—funded by a $23.6M Gates Foundation grant—to mass-produce needle-free vaccines and support larger clinical trials and regulatory approvals. Micron’s technology aims to expand vaccine access in low- and middle-income countries, improve patient acceptance in higher-income markets, and strengthen US national, veteran, and military health. Micron partners with the Bill & Melinda Gates Foundation, the CDC, PATH, and the Georgia Research Alliance and previously received a Gates grant in 2017 that enabled its first pediatric clinical trial. Micron Biomedical is an Atlanta-based life sciences company advancing dissolvable microarray-based drug and vaccine administration technology. Its patented microarray technology enables drugs and vaccines that today require cold storage and injection to be self-administered or caregiver-administered within minutes without refrigeration or a skilled health professional. The company aims to bring its dissolvable microarray products to markets globally. Micron has partnered with or received funding from private and public pharmaceutical and biotech companies as well as the Bill & Melinda Gates Foundation, the CDC, UNICEF, PATH and the Georgia Research Alliance. The company is led by CEO Steven Damon. The Series A extension will further support commercialization and global market efforts. Micron Biomedical is a clinical-stage life sciences company advancing its Micro Array Patch (MAP) technology to enable self-administration and less-skilled caregiver administration of drugs and vaccines without needles. Led by CEO Steven Damon and based in Atlanta, GA, the company’s pipeline includes vaccine and drug products partnered with pharmaceutical companies, foundations, and government agencies. Micron has demonstrated clinical efficacy for its MAP technology and since inception has supported R&D with more than $40 million in non-dilutive financing. The company intends to use the new funds to develop commercial manufacturing capacity, which is currently underway. Micron has received support and funding from foundations and public health organizations that have partnered on development and trials.